Do analysts rate BCTX or IMRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, BCTX or IMRN?

Immuron has higher revenue and earnings than Briacell Therap. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A Immuron $5.47M 1.61 -$2.50M N/A N/A

Is BCTX or IMRN more profitable?

Immuron's return on equity of 0.00% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% Immuron N/A N/A N/A

Which has preferable earnings and valuation, ATNM or IMRN?

Immuron has lower revenue, but higher earnings than Actinium Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actinium Pharmaceuticals $35.09M 0.96 -$48.82M $0.36 2.97 Immuron $5.47M 1.61 -$2.50M N/A N/A

Is ATNM or IMRN more profitable?

Immuron's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Immuron N/A N/A N/A

Do analysts recommend IMRN or ALGS?

Aligos Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 623.68%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has higher earnings & valuation, IMRN or ALGS?

Immuron has higher revenue and earnings than Aligos Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $5.47M 1.61 -$2.50M N/A N/A Aligos Therapeutics $2.19M 15.16 -$24.19M -$7.30 N/A

Do analysts rate IMRN or IMMP?

Prima BioMed has a consensus price target of $110.00, suggesting a potential upside of 2,609.36%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Prima BioMed is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40

Which has stronger valuation and earnings, IMRN or IMMP?

Immuron has higher earnings, but lower revenue than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $5.47M 1.61 -$2.50M N/A N/A Prima BioMed $16.40M 1.82 -$53.82M N/A N/A

Is IMRN or IMMP more profitable?

Company Net Margins Return on Equity Return on Assets Immuron N/A N/A N/A Prima BioMed N/A N/A N/A

Do analysts rate IMRN or MCRB?

Seres Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 525.00%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger valuation & earnings, IMRN or MCRB?

Seres Therapeutics has lower revenue, but higher earnings than Immuron. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $5.47M 1.61 -$2.50M N/A N/A Seres Therapeutics $790K 34.60 $5.70M -$2.43 N/A

Immuron (IMRN) Competitors

$1.13 +0.04 (+3.58%)

As of 11:51 AM Eastern

Compare

IMRN vs. BCTX, ATNM, ALGS, IMMP, and MCRB

Should you buy Immuron stock or one of its competitors? Immuron's main competitors and comparable companies include Briacell Therap (BCTX), Actinium Pharmaceuticals (ATNM), Aligos Therapeutics (ALGS), Prima BioMed (IMMP), and Seres Therapeutics (MCRB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immuron compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Immuron has higher revenue and earnings than Briacell Therap.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Immuron	$5.47M	1.61	-$2.50M	N/A	N/A

Immuron's return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Immuron	N/A	N/A	N/A

Briacell Therap has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, Immuron has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 7.0% of Immuron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Briacell Therap had 2 more articles in the media than Immuron. MarketBeat recorded 2 mentions for Briacell Therap and 0 mentions for Immuron. Briacell Therap's average media sentiment score of 0.00 equaled Immuron'saverage media sentiment score.

Company	Overall Sentiment
Briacell Therap	Neutral
Immuron	Neutral

Summary

Immuron beats Briacell Therap on 5 of the 8 factors compared between the two stocks.

How does Immuron compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 7.0% of Immuron shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Actinium Pharmaceuticals has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Immuron has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Immuron's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Immuron	N/A	N/A	N/A

In the previous week, Actinium Pharmaceuticals' average media sentiment score of 0.00 equaled Immuron'saverage media sentiment score.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
Immuron	Neutral

Actinium Pharmaceuticals currently has a consensus price target of $5.00, suggesting a potential upside of 367.29%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Actinium Pharmaceuticals is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Immuron has lower revenue, but higher earnings than Actinium Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	0.96	-$48.82M	$0.36	2.97
Immuron	$5.47M	1.61	-$2.50M	N/A	N/A

Summary

Immuron beats Actinium Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Immuron compare to Aligos Therapeutics?

Immuron (NASDAQ:IMRN) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Aligos Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 623.68%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

0.1% of Immuron shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 7.0% of Immuron shares are owned by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Aligos Therapeutics had 3 more articles in the media than Immuron. MarketBeat recorded 3 mentions for Aligos Therapeutics and 0 mentions for Immuron. Aligos Therapeutics' average media sentiment score of 0.18 beat Immuron's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Immuron	Neutral
Aligos Therapeutics	Neutral

Immuron has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Immuron's return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Aligos Therapeutics	-241.01%	-160.72%	-92.30%

Immuron has higher revenue and earnings than Aligos Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$5.47M	1.61	-$2.50M	N/A	N/A
Aligos Therapeutics	$2.19M	15.16	-$24.19M	-$7.30	N/A

Immuron has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market.

Summary

Aligos Therapeutics beats Immuron on 10 of the 15 factors compared between the two stocks.

How does Immuron compare to Prima BioMed?

Immuron (NASDAQ:IMRN) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Immuron has higher earnings, but lower revenue than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$5.47M	1.61	-$2.50M	N/A	N/A
Prima BioMed	$16.40M	1.82	-$53.82M	N/A	N/A

Prima BioMed has a consensus price target of $110.00, suggesting a potential upside of 2,609.36%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Prima BioMed is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, Immuron's average media sentiment score of 0.00 equaled Prima BioMed'saverage media sentiment score.

Company	Overall Sentiment
Immuron	Neutral
Prima BioMed	Neutral

Immuron has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market.

0.1% of Immuron shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 7.0% of Immuron shares are owned by insiders. Comparatively, 3.1% of Prima BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Prima BioMed	N/A	N/A	N/A

Summary

Prima BioMed beats Immuron on 8 of the 10 factors compared between the two stocks.

How does Immuron compare to Seres Therapeutics?

Immuron (NASDAQ:IMRN) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Immuron has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Immuron's return on equity of 0.00% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

Seres Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 525.00%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Immuron has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Seres Therapeutics has lower revenue, but higher earnings than Immuron.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$5.47M	1.61	-$2.50M	N/A	N/A
Seres Therapeutics	$790K	34.60	$5.70M	-$2.43	N/A

In the previous week, Seres Therapeutics had 1 more articles in the media than Immuron. MarketBeat recorded 1 mentions for Seres Therapeutics and 0 mentions for Immuron. Seres Therapeutics' average media sentiment score of 0.75 beat Immuron's score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Immuron	Neutral
Seres Therapeutics	Positive

0.1% of Immuron shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 7.0% of Immuron shares are held by insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Seres Therapeutics beats Immuron on 8 of the 14 factors compared between the two stocks.

Get Immuron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRN vs. The Competition

Export

Metric	Immuron	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.11M	$3.75B	$7.05B	$13.29B
Dividend Yield	N/A	3.66%	2.53%	16.47%
P/E Ratio	N/A	13.63	275.25	25.94
Price / Sales	1.67	1,173.54	571.70	85.02
Price / Cash	N/A	118.37	77.41	52.81
Price / Book	1.20	16.15	10.82	6.24
Net Income	-$2.50M	-$22.65M	$3.50B	$382.01M
7 Day Performance	-0.09%	-4.50%	-2.58%	-1.66%
1 Month Performance	-38.64%	-13.64%	-8.03%	-5.86%
1 Year Performance	-50.15%	7.48%	2.31%	-1.93%

Immuron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRN Immuron	0.1319 of 5 stars	$1.13 +3.6%	N/A	-50.6%	$9.11M	$5.47M	N/A	7
BCTX Briacell Therap	0.2147 of 5 stars	$4.28 +4.9%	N/A	-68.3%	$37.24M	N/A	N/A	4	News Coverage
ATNM Actinium Pharmaceuticals	1.6981 of 5 stars	$1.12 -1.8%	$5.00 +346.4%	-32.3%	$35.21M	$35.09M	N/A	25
ALGS Aligos Therapeutics	2.2491 of 5 stars	$5.63 +0.2%	$38.50 +583.8%	-45.9%	$35.16M	$31.52M	N/A	82
IMMP Prima BioMed	2.6922 of 5 stars	$4.65 -1.3%	$110.00 +2,265.6%	-90.2%	$34.27M	$14.56M	N/A	2,021

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRN) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuron (IMRN) Competitors

IMRN vs. BCTX, ATNM, ALGS, IMMP, and MCRB

How does Immuron compare to Briacell Therap?

Summary

How does Immuron compare to Actinium Pharmaceuticals?

Summary

How does Immuron compare to Aligos Therapeutics?

Summary

How does Immuron compare to Prima BioMed?

Summary

How does Immuron compare to Seres Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN vs. The Competition

Immuron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuron (IMRN) Competitors

IMRN vs. BCTX, ATNM, ALGS, IMMP, and MCRB

How does Immuron compare to Briacell Therap?

Do analysts rate BCTX or IMRN?

Which has higher valuation & earnings, BCTX or IMRN?

Is BCTX or IMRN more profitable?

Which has more volatility & risk, BCTX or IMRN?

Do insiders & institutionals believe in BCTX or IMRN?

Does the media prefer BCTX or IMRN?

Summary

How does Immuron compare to Actinium Pharmaceuticals?

Do insiders and institutionals hold more shares of ATNM or IMRN?

Which has more risk and volatility, ATNM or IMRN?

Is ATNM or IMRN more profitable?

Does the media refer more to ATNM or IMRN?

Do analysts prefer ATNM or IMRN?

Which has preferable earnings and valuation, ATNM or IMRN?

Summary

How does Immuron compare to Aligos Therapeutics?

Do analysts recommend IMRN or ALGS?

Do insiders & institutionals believe in IMRN or ALGS?

Does the media favor IMRN or ALGS?

Is IMRN or ALGS more profitable?

Which has higher earnings & valuation, IMRN or ALGS?

Which has more risk and volatility, IMRN or ALGS?

Summary

How does Immuron compare to Prima BioMed?

Which has stronger valuation and earnings, IMRN or IMMP?

Do analysts rate IMRN or IMMP?

Does the media favor IMRN or IMMP?

Which has more risk and volatility, IMRN or IMMP?

Do insiders & institutionals believe in IMRN or IMMP?

Is IMRN or IMMP more profitable?

Summary

How does Immuron compare to Seres Therapeutics?

Is IMRN or MCRB more profitable?

Do analysts rate IMRN or MCRB?

Which has more volatility & risk, IMRN or MCRB?

Which has stronger valuation & earnings, IMRN or MCRB?

Does the media prefer IMRN or MCRB?

Do institutionals & insiders hold more shares of IMRN or MCRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN vs. The Competition

Immuron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools